NF-kB2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1629-1637

  Nadiminty, Nagalakshmi ^a   Tummala, Ramakumar ^a   Liu, Chengfei ^a   Yang, Joy ^a   Lou, Wei ^a   Evans, Christopher P ^a,b   Gao, Allen C ^a,b,c  

^a Department of Urology ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT HAIRPIN RNA; ANTIANDROGEN; DRUG DERIVATIVE; PHENYLTHIOHYDANTOIN;

ARTICLE; CELL GROWTH; CELL STRAIN LNCAP; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING; ALTERNATIVE RNA SPLICING; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; ANALOGS AND DERIVATIVES;

ALTERNATIVE SPLICING; ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; MALE; NF-KAPPA B P52 SUBUNIT; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84882274167     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0027     Document Type: Article

References (22)

1. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068-72.
2. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. Androgen receptors in endocrinetherapy-resistant human prostate cancer. Int J Cancer 1991;48: 189-93.
3. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
4. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73: 483-9.
5. Karin M. NF-kB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
6. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001;7:401-9.
7. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaBinducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 2004; 279:30099-105.
8. Qing G, Xiao G. Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J Biol Chem 2005;280: 9765-8.
9. Qing G, Qu Z, Xiao G. Regulation of NF-kappa B2 p100 processing by its cis-acting domain. J Biol Chem 2005;280:18-27.
10. Xiao G, Rabson AB, Young W, Qing G, Qu Z. Alternative pathways of NF-kappaB activation: A double-edged sword in health and disease. Cytokine Growth Factor Rev 2006;17:281-93.
11. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000;19:1123-31.
12. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, et al. Nuclear localization of nuclear factorkappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006;12:5741-5.
13. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC. NF-kB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgendeprivation. Prostate 2008;68:1725-33.
14. Nadiminty N, Dutt S, Tepper C, Gao AC. Microarray analysis reveals potential target genes of NF-k2/p52 in LNCaP prostate cancer cells. Prostate 2010;70:276-87.
15. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, et al. Aberrant activation of the androgen receptor by NF-kB2/p52 in prostate cancer cells. Cancer Res 2010;70:3309-19.
16. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-kappaB p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 2006;103:7264-9.
17. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
18. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25.
19. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011;6:e19059.
20. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
21. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require fulllength androgen receptor. Proc Natl Acad Sci U S A 2010;107: 16759-65.
22. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72: 3457-62.